← Back to Search

Phosphodiesterase-5 (PDE-5) Inhibitor

Sildenafil for Heart Failure

Phase 4
Waitlist Available
Led By Joe R Anderson, PharmD
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours and 3 months
Awards & highlights

Study Summary

The purpose of the study is to evaluate whether sildenafil helps treat heart failure. Some patients with heart failure have high blood pressure in the lungs (referred to as "pulmonary hypertension"). Sildenafil is a medication that is used to treat high blood pressure in the lungs and may reduce symptoms of heart failure. Studies have looked at the short-term benefit of sildenafil in patients with congestive heart failure, but this study will look at the longer-term benefits of 12 weeks of therapy with sildenafil.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours and 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in 6-minute walk distance
Secondary outcome measures
Change in quality of life
Change in the level of neurohormones (b-type natriuretic peptide, catecholamines, ET-1)
Changes in peak oxygen consumption (measured by cardiopulmonary exercise testing)

Side effects data

From 2018 Phase 4 trial • 6 Patients • NCT01642407
50%
Bronchitis
50%
Nasopharyngitis
50%
Upper respiratory tract infection
33%
Headache
33%
Epistaxis
33%
Diarrhoea
33%
Gastroenteritis
17%
Vision blurred
17%
Eczema
17%
Rash
17%
Flushing
17%
Alanine aminotransferase increased
17%
Ammonia increased
17%
Aspartate aminotransferase increased
17%
Weight increased
17%
Dysmenorrhoea
17%
Erection increased
17%
Pulmonary arterial hypertension
17%
Rhinitis allergic
17%
Acne
17%
Dermatitis diaper
17%
Dry skin
17%
Visual acuity reduced transiently
17%
Colitis
17%
Molluscum contagiosum
17%
Streptococcal infection
17%
Blood urine present
17%
Myalgia
17%
Cardiac failure
17%
Conjunctivitis allergic
17%
Dental caries
17%
Vomiting
17%
Chest pain
17%
Feeling abnormal
17%
Influenza
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sildenafil

Trial Design

1Treatment groups
Experimental Treatment
Group I: SildenafilExperimental Treatment1 Intervention
All patients will receive open-label treatment with sildenafil.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sildenafil
FDA approved

Find a Location

Who is running the clinical trial?

University of New MexicoLead Sponsor
372 Previous Clinical Trials
3,528,789 Total Patients Enrolled
1 Trials studying Heart Failure
13 Patients Enrolled for Heart Failure
Joe R Anderson, PharmDPrincipal InvestigatorUniversity of New Mexico College of Pharmacy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure
Joe R. Anderson 2008. "Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00793338.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top